CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 654-660

  Chiorean, E G ^a   Von Hoff, D D ^b   Reni, M ^c   Arena, F P ^d   Infante, J R ^e   Bathini, V G ^f   Wood, T E ^g   Mainwaring, P N ^h   Muldoon, R T ⁱ   Clingan, P R ^j   Kunzmann, V ^k   Ramanathan, R K ^b   Tabernero, J ^l   Goldstein, D ^m   McGovern, D ⁿ   Lu, B ⁿ   Ko, A ⁿ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Mater Private Centre for Haematology and Oncology   (Australia)

ⁱ Genesis Cancer Center   (United States)

^j Southern Medical Day Care Centre   (Australia)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m PRINCE OF WALES HOSPITAL   (Australia)

ⁿ CELGENE CORPORATION   (United States)

more..

Author keywords

CA19 9; Chemotherapy; MPACT; Nab paclitaxel; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; DEOXYCYTIDINE; PHARMACOLOGICAL BIOMARKER;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPLORATORY RESEARCH; HUMAN; MAJOR CLINICAL STUDY; METASTATIC PANCREATIC CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; ADENOCARCINOMA; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; ALBUMINS; BIOMARKERS, PHARMACOLOGICAL; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84964614126     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw006     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society, 2014.
2. Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep 2011; 13: 195-205.
3. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-55.
4. Koprowski H, Steplewski Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971.
5. Boeck S, Stieber P, Holdenrieder S et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255-264.
6. Bauer TM, El-Rayes BF, Li X et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 2013; 119: 285-292.
7. Ko AH, Hwang J, Venook AP et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005; 93: 195-199.
8. Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997; 1: 106-112.
9. Saad ED, Machado MC, Wajsbrot D et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002; 32: 35-41.
10. Stemmler J, Stieber P, Szymala AM et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003; 26: 462-467.
11. Ziske C, Schlie C, Gorschluter M et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417.
12. Reni M, Cereda S, Balzano G et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-2639.
13. Hess V, Glimelius B, Grawe P et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132-138.
14. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
15. Goldstein D, El-Maraghi RH, Hammel P et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015; 107: dju413.
16. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554.
17. Tabernero J, Chiorean EG, Infante R et al. Prognostic factors of survival in a randomized phase III trial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015; 20: 143-150.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
19. Robert M, Jarlier M, Conroy T et al. Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4). ASCO Meeting Abstracts 2014. J Clin Oncol 2014; (5s suppl): abstr 4115.